Literature DB >> 12642689

Role of MRIT/cFLIP in protection against chemotherapy-induced apoptosis.

Hittu Matta1, Michael T Eby, Adi F Gazdar, Preet M Chaudhary.   

Abstract

MRIT (Mach-related inducer of toxicity)/cFLIP (cellular FADD like interlukin1-beta converting enzyme inhibitory protein) is a proteolytically inactive structural homologue of caspase-8, which is known to protect against death receptors-induced apoptosis by blocking the activation of caspase-8. We have observed that exogenous expression of MRITalpha1/cFLIP(L) isoform also protects against cell death induced by a diverse group of chemotherapeutic drugs with different mechanisms of action, including doxorubicin, etoposide, cytosine arabinoside, daunorubicin, chlorambucil and cisplatin. However, MRITalpha1/cFLIP(L) failed to protect against apoptosis induced by paclitaxel and vincristine, two microtubule-damaging agents. Although MRITalpha1/cFLIP(L) protects against chemotherapy-induced apoptosis in both solid tumor and hematopoietic cell lines, this effect was more pronounced in the former. MRITalpha1/cFLIP(L) expression is decreased during drug-induced apoptosis and exogenous expression of MRITalpha1/cFLIP(L) delays the activation of caspase-8 and -3 during drug- induced apoptosis. These results suggest that MRITalpha1/cFLIPL may be an important determinant of both death receptor- and chemotherapy-induced apoptosis and strategies aimed at downregulating its expression deserve further study as a way to overcome multidrug resistance to cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12642689     DOI: 10.4161/cbt.315

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  7 in total

1.  Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts.

Authors:  Krithi Rao-Bindal; Chethan K Rao; Ling Yu; Eugenie S Kleinerman
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

2.  Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling.

Authors:  Pachiyappan Kamarajan; Nian-Kang Sun; Chuck C-K Chao
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

Review 3.  Cellular FLICE-inhibitory protein: an attractive therapeutic target?

Authors:  Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2003-08       Impact factor: 6.902

Review 4.  The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma.

Authors:  Simin Kiany; Douglas Harrison; Nancy Gordon
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

5.  Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes.

Authors:  R Mezencev; L V Matyunina; G T Wagner; J F McDonald
Journal:  Cancer Gene Ther       Date:  2016-12-02       Impact factor: 5.987

Review 6.  Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL).

Authors:  Mohammed I Y Elmallah; Olivier Micheau
Journal:  Mar Drugs       Date:  2015-11-13       Impact factor: 5.118

7.  Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs.

Authors:  Eun-Ae Kim; Sang-Woo Kim; Jehyun Nam; Eon-Gi Sung; In-Hwan Song; Joo-Young Kim; Taeg Kyu Kwon; Tae-Jin Lee
Journal:  Oncotarget       Date:  2016-05-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.